Maravai LifeSciences

MRVI

Market cap $516M

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.06 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-984.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2025, at 10:00 a.m. EST, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 19, 2025, at 10:00 a.m. GMT, Raj Asarpota, Chief Fin.

Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Chanfeng Zhao - Senior VP & Chief Scientific Officer Conference Call Participants Justin Bowers - Deutsche Bank AG, Research Division Madeline Mollman - Wolfe Research, LLC Thomas Peterson - Robert W. Baird & Co. Incorporated, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, everyone.

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.02 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co.

Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2025 financial and operating results after the market close on Thursday, November 6, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 579-2543 or (785) 424-1789 and reference M.